Abstract
Lung cancer remains a leading cause of cancer-related mortality, with heterogeneous outcomes, underscoring the need for robust prognostic biomarkers. Circulating tumor DNA (ctDNA) enables detection of actionable mutations and may provide prognostic information; however, many patients lack detectable alterations, limiting its utility for molecular-based risk stratification. We analyzed plasma from 617 treatment-naïve patients using targeted next-generation sequencing for ctDNA and immunoassays to quantify circulating H3K27Me3-nucleosomes. Survival analyses included 514 patients with ≥8-month follow-up. Elevated H3K27Me3-nucleosome levels were independently associated with poorer overall survival. Patients with levels <56 ng/mL had significantly longer survival than those with higher concentrations (26 vs 12 months; p<0.0001), including in ctDNA-negative patients (29 vs 12 months; p<0.0001). A multivariable Cox model integrating H3K27Me3, stage, mutation, and age showed good performance (C-index 0.80) and was validated in an independent cohort. Circulating H3K27Me3-nucleosomes enable clinically relevant risk stratification at diagnosis, supporting more precise patient management in lung cancer.

This publication has 45 references indexed in Scilit: